Prior to joining National Institute of Health, Dr. Tamiz had held scientific and management positions in research and development of therapeutic programs at Corvas International (acquired by Dendreon), CovX (Pfizer), and Alba Therapeutics (Cephalon). His background includes leading multidisciplinary drug discovery and development teams, analytical method development, formulation, and manufacturing. Dr. Tamiz has a successful track record of transforming science and technologies into a number of clinically viable products in several therapeutic areas.
Dr. Tamiz received his Ph.D. at University of Oregon and conducted postdoctoral research at the Department of Neuroscience – Georgetown University Medical center. At Oregon, he studied the design and synthesis of N-Methyl-D-aspartic acid inhibitors for the treatment of neurological disorders. Dr. Tamiz has more than 50 publications and patents.
Last Modified January 30, 2015